ZA917960B - Antibody preparation. - Google Patents

Antibody preparation.

Info

Publication number
ZA917960B
ZA917960B ZA917960A ZA917960A ZA917960B ZA 917960 B ZA917960 B ZA 917960B ZA 917960 A ZA917960 A ZA 917960A ZA 917960 A ZA917960 A ZA 917960A ZA 917960 B ZA917960 B ZA 917960B
Authority
ZA
South Africa
Prior art keywords
ser
tyr
gly
asp
asn
Prior art date
Application number
ZA917960A
Other languages
English (en)
Inventor
Scott David Gorman
Edward Graham Routledge
Herman Waldmann
Original Assignee
Scott David Gorman
Edward Graham Routledge
Herman Waldmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scott David Gorman, Edward Graham Routledge, Herman Waldmann filed Critical Scott David Gorman
Publication of ZA917960B publication Critical patent/ZA917960B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA917960A 1990-10-05 1991-10-04 Antibody preparation. ZA917960B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909021679A GB9021679D0 (en) 1990-10-05 1990-10-05 Antibody preparation

Publications (1)

Publication Number Publication Date
ZA917960B true ZA917960B (en) 1993-04-05

Family

ID=10683287

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA917960A ZA917960B (en) 1990-10-05 1991-10-04 Antibody preparation.

Country Status (12)

Country Link
EP (1) EP0504350B1 (de)
JP (1) JP3081641B2 (de)
KR (1) KR100245564B1 (de)
AT (1) ATE169058T1 (de)
AU (1) AU651623B2 (de)
CA (1) CA2070659C (de)
DE (1) DE69129896T2 (de)
ES (1) ES2121788T3 (de)
GB (2) GB9021679D0 (de)
NZ (1) NZ240080A (de)
WO (1) WO1992006193A1 (de)
ZA (1) ZA917960B (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US6106835A (en) * 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US5872222A (en) * 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6593132B1 (en) 1997-04-30 2003-07-15 Twinstrand Therapeutics Inc. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
DE69841139D1 (de) 1997-07-14 2009-10-22 Univ Liege Mutationen im myostatingen steigern muskelmasse in säugetieren
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6531125B1 (en) 1999-03-02 2003-03-11 Twinstrand Therapeutics Inc. Antiviral ricin-like proteins
CA2305716A1 (en) 1999-05-28 2000-11-28 University Of Guelph Method for assay of wbpm
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1499635B8 (de) 2002-05-02 2014-04-16 David Lovejoy Teneurin c-terminal assoziierte peptide und deren verwendungen
WO2005012526A1 (en) 2003-08-04 2005-02-10 The Hospital For Sick Children Lafora's disease gene
US7427670B2 (en) 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
WO2006087196A2 (en) 2005-02-16 2006-08-24 University Of Zürich Methods for treating cancer using an immunotoxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by mmp-2 or mmp-9
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
KR101722261B1 (ko) * 2006-10-02 2017-04-03 메다렉스, 엘.엘.시. Ｃｘｃｒ4에 결합하는 인간 항체 및 이의 용도
EP2076287A2 (de) 2006-10-12 2009-07-08 Wyeth Verfahren und zusammensetzungen mit verringerter opaleszenz
EP2064315B1 (de) 2006-11-03 2015-05-13 Wyeth LLC Glycolysehemmstoffe in zellkulturen
US20110294782A1 (en) 2006-11-10 2011-12-01 Massachusetts Institute Of Technology Small molecule pak inhibitors
DE102006062398A1 (de) 2006-12-20 2008-06-26 Edi (Experimentelle & Diagnostische Immunologie) Gmbh Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
CA2679941C (en) 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
JP2012504939A (ja) 2008-09-23 2012-03-01 ワイス・エルエルシー 架橋結合タンパク質による活性化シグナルの産生を予測するための方法
EP2362767B1 (de) 2008-10-29 2017-12-06 Ablynx N.V. Formulierungen von einzeldomänen-antigen-bindungsmolekülen
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
WO2010091182A2 (en) 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
US8765916B2 (en) 2009-04-29 2014-07-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ERG monoclonal antibodies
CA2766861A1 (en) 2009-07-09 2011-01-13 F. Hoffmann-La Roche Ag In vivo tumor vasculature imaging
RU2644335C2 (ru) 2010-03-03 2018-02-08 Зе Юниверсити Оф Бритиш Коламбия Эпитоп, специфичный к олигомеру амилоида бета, и антитела
CN108314733A (zh) 2010-07-16 2018-07-24 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
EP2606119A1 (de) 2010-08-20 2013-06-26 Wyeth LLC Zellkultur aus wachstumsfaktorfreien adaptierten zellen
EP3974453A3 (de) 2010-11-16 2022-08-03 Amgen Inc. Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen
CN103547592A (zh) 2011-03-30 2014-01-29 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
US20140322758A1 (en) 2011-10-21 2014-10-30 Pfizer Inc. Addition of iron to improve cell culture
EP3718556A3 (de) 2012-08-31 2020-12-30 University Of Virginia Patent Foundation Zielpeptide für immuntherapie und diagnostik
EP4088737A3 (de) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target-peptide für therapie und diagnostik von kolorektalkarzinomen
AU2013329372B2 (en) 2012-10-08 2018-07-12 St. Jude Children's Research Hospital Therapies based on control of regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis
CA2894885A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
WO2015140708A1 (en) 2014-03-19 2015-09-24 Pfizer Inc. Method of cell culture
CA2945816A1 (en) 2014-04-15 2015-10-22 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
JP7020909B2 (ja) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
AU2016306304A1 (en) 2015-08-07 2018-03-22 The University Of Birmingham Identification of class I MHC associated glycopertides as targets for cancer immunotherapy
CA2999224C (en) 2015-09-23 2023-10-24 Pfizer Inc. Cells and method of cell culture
GB201520191D0 (en) 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
AU2017247701B2 (en) 2016-04-05 2022-11-10 Pfizer Inc. Cell culture process
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3596206A1 (de) 2017-03-16 2020-01-22 Pfizer Inc Tyrosinprototrophie
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
EP3681989A1 (de) 2017-09-15 2020-07-22 Bristol-Myers Squibb Company Online-überwachung der biomassekapazität während der grossserienproduktion von polypeptiden von interesse
EP3743101A2 (de) 2018-01-25 2020-12-02 ACM Biolabs Pte Ltd Ein lösliches verkapseltes antigen enthaltende polymersome sowie verfahren zu deren herstellung und verwendung
US12325875B2 (en) 2018-03-16 2025-06-10 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
KR102711673B1 (ko) 2018-03-26 2024-09-30 글리카노스틱스 에스.알.오. 단백질 글리코프로파일링의 수단 및 방법
WO2020053325A1 (en) 2018-09-12 2020-03-19 Acm Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
EP3891292A1 (de) 2018-12-06 2021-10-13 Pfizer Inc. Zellen mit reduzierter inhibitorproduktion und verfahren zur verwendung davon
US20220332799A1 (en) 2019-09-04 2022-10-20 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies
WO2022218957A1 (en) 2021-04-12 2022-10-20 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
JP2024529771A (ja) 2021-08-26 2024-08-08 グリカノスティクス エス．アール．オー． がん診断のための糖タンパク質バイオマーカー
EP4396583A1 (de) 2021-09-14 2024-07-10 Glycanostics s.r.o. Verwendung von lektinen zur bestimmung von mammaglobin-a-glykoformen bei brustkrebs
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
US20250304911A1 (en) 2022-02-02 2025-10-02 Pfizer Inc. Cysteine prototrophy
CN115073602B (zh) * 2022-05-30 2023-10-03 苏州百道医疗科技有限公司 一种抗cd3重组兔单克隆抗体及其应用
EP4698631A1 (de) 2023-04-21 2026-02-25 Pfizer Inc. Verbesserte zellen und zellkulturen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation

Also Published As

Publication number Publication date
AU651623B2 (en) 1994-07-28
GB2249310B (en) 1994-08-03
KR100245564B1 (ko) 2000-02-15
WO1992006193A1 (en) 1992-04-16
ES2121788T3 (es) 1998-12-16
GB2249310A (en) 1992-05-06
JP3081641B2 (ja) 2000-08-28
NZ240080A (en) 1995-05-26
AU8546891A (en) 1992-04-28
DE69129896D1 (de) 1998-09-03
GB9021679D0 (en) 1990-11-21
EP0504350B1 (de) 1998-07-29
CA2070659C (en) 2001-04-24
DE69129896T2 (de) 1998-12-10
JPH05502384A (ja) 1993-04-28
GB9121126D0 (en) 1991-11-13
EP0504350A1 (de) 1992-09-23
CA2070659A1 (en) 1992-04-06
KR927003816A (ko) 1992-12-18
ATE169058T1 (de) 1998-08-15

Similar Documents

Publication Publication Date Title
GB2249310B (en) Antibody preparation
GB9206422D0 (en) Antibody preparation
ATE384792T1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
CA2212750A1 (en) Humanized antibodies against cd3
CA2103059A1 (en) Method for making humanized antibodies
GR1002306B (el) Αναλυση και διαταξη συγκολλησεως στηλης.
DK0458841T3 (da) Fremgangsmåde til anvendelse og fremstilling af peptider
SE9304060D0 (sv) Sätt att selektera specifika bakteriofager
DK0724456T3 (da) CD40-Antistoffer
EP1266965A3 (de) Rekombinante Antikörper zur humanen Therapie
MY111682A (en) Altered antibodies and their preparations.
NZ228560A (en) Cross-linked heteroconjugates comprising at least two molecules capable of binding to different antigens on the surface of individual lymphocytes
AU629135B2 (en) Monoclonal antibody against melanoma
PT840618E (pt) Inducao de tolerancia imunologica atraves de anticorpos anti-cd4 nao-depletores
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
HU9602570D0 (en) Process for producing immunoglobulines from fractions produced with fractioning human blood-plasma
EP0109434A4 (de) In vitro diagnoseverfahren unter verwendung von monoklonalen antikörpern gegen konnektive gewebeproteine.
EP0307476A4 (en) Bilirubin antigen, monoclonal antibody therefor, process for their preparation, and their use
DE3570677D1 (en) Acino-foetal differentiation proteins associated with cancer of the pancreas, antiserum and monoclonal antibodies against these proteins and processes for their preparation
WO1994021812A3 (en) Hepatitis b escape mutant specific binding molecules
Coppo et al. IgA1 and IgA2 in circulating immune complexes and in renal deposits of Berger's and Schönlein-Henoch glomerulonephritis
GB2233091B (en) Immunoassays using monoclonal antibodies directed against natural binding proteins
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
DE68912165D1 (de) Monoklonaler Antikörper, der fähig ist, ein mit humaner Arteriosklerose assoziiertes Antigen zu erkennen und Verfahren zu seiner Herstellung.
MD752C2 (ro) Procedeu de preparare a diagnosticumului pentru identificarea antigenului rotavirusurilor în reacţia de coaglutinare